284. Zarei, M.; Barroso, E.; Palomer, X.; Dai, J.; Rada, P.; Quesada-López, T.; Escolà-Gil, J.C.; Cedó, L.; Zali, M.R.; Molaei, M.; et al. Hepatic regulation of VLDL receptor by PPARβ/δ and FGF21 modulates non-alcoholic fatty liver disease. *Mol. Metab.* **2018**, *8*, 117–131. [CrossRef] [PubMed]

285. Doktorova, M.; Zwarts, I.; Van Zutphen, T.; Van DIjk, T.H.; Bloks, V.W.; Harkema, L.; De Bruin, A.; Downes, M.; Evans, R.M.; Verkade, H.J.; et al. Intestinal PPARδ protects against diet-induced obesity, insulin resistance and dyslipidemia. *Sci. Rep.* **2017**, *7*, [CrossRef] [PubMed]

286. Wagner, N.; Wagner, K.-D. PPAR Beta/Delta and the Hallmarks of Cancer. *Cells* **2020**, *9*, 1133. [CrossRef]

287. Imai, T.; Takakuwa, R.; Marchand, S.; Dentz, E.; Bornert, J.M.; Messaddeq, N.; Wendling, O.; Mark, M.; Desvergne, B.; Wahli, W.; et al. Peroxisome proliferator-activated receptor γ is required in mature white and brown adipocytes for their survival in the mouse. *Proc. Natl. Acad. Sci. USA* **2004**, *101*, 4543–4547. [CrossRef]

288. Wang, F.; Mullican, S.E.; DiSpirito, J.R.; Peed, L.C.; Lazar, M.A. Lipatrophy and severe metabolic disturbance in mice with fat-specific deletion of PPARγ. *Proc. Natl. Acad. Sci. USA* **2013**, *110*, 18656–18661. [CrossRef] [PubMed]

289. Jonker, J.W.; Suh, J.M.; Atkins, A.R.; Ahmadian, M.; Li, P.; Whyte, J.; He, M.; Juguilon, H.; Yin, Y.Q.; Phillips, C.T.; et al. A PPARγ-FGF1 axis is required for adaptive adipose remodelling and metabolic homeostasis. *Nature* **2012**, *485*, 391–394. [CrossRef] [PubMed]

290. Blanchard, P.G.; Moreira, R.J.; Castro, É.; Caron, A.; Côté, M.; Andrade, M.L.; Oliveira, T.E.; Ortiz-Silva, M.; Peixoto, A.S.; Dias, F.A.; et al. PPARγ is a major regulator of branched-chain amino acid blood levels and catabolism in white and brown adipose tissues. *Metabolism* **2018**, *89*, 27–38. [CrossRef] [PubMed]

291. Dutchak, P.A.; Katafuchi, T.; Bookout, A.L.; Choi, J.H.; Yu, R.T.; Mangelsdorf, D.J.; Kliewer, S.A. Fibroblast growth factor-21 regulates PPARγ activity and the antidiabetic actions of thiazolidinediones. *Cell* **2012**, *148*, 556–567. [CrossRef] [PubMed]

292. Matsusue, K.; Haluzik, M.; Lambert, G.; Yim, S.-H.; Gavrilova, O.; Ward, J.M.; Brewer, B.; Reitman, M.L.; Gonzalez, F.J. Liver-specific disruption of PPARγ in leptin-deficient mice improves fatty liver but aggravates diabetic phenotypes. *J. Clin. Invest.* **2003**, *111*, 737–747. [CrossRef]

293. Matsusue, K.; Kusakabe, T.; Noguchi, T.; Takiguchi, S.; Suzuki, T.; Yamano, S.; Gonzalez, F.J. Hepatic Steatosis in Leptin-Deficient Mice Is Promoted by the PPARγ Target Gene Fsp27. *Cell Metab.* **2008**, *7*, 302–311. [CrossRef] [PubMed]

294. Wang, W.; Xu, M.J.; Cai, Y.; Zhou, Z.; Cao, H.; Mukhopadhyay, P.; Pacher, P.; Zheng, S.; Gonzalez, F.J.; Gao, B. Inflammation is independent of steatosis in a murine model of steatohepatitis. *Hepatology* **2017**, *66*, 108–123. [CrossRef] [PubMed]

295. Hasenfuss, S.C.; Bakiri, L.; Thomsen, M.K.; Williams, E.G.; Auwerx, J.; Wagner, E.F. Regulation of steatohepatitis and PPARγ signaling by distinct AP-1 dimers. *Cell Metab.* **2014**, *19*, 84–95. [CrossRef] [PubMed]

296. Lee, Y.K.; Park, J.E.; Lee, M.; Hardwick, J.P. Hepatic lipid homeostasis by peroxisome proliferator-activated receptor gamma 2. *Liver Res.* **2018**, *2*, 209–215. [CrossRef] [PubMed]

297. Panasyuk, G.; Espeillac, C.; Chauvin, C.; Pradelli, L.A.; Horie, Y.; Suzuki, A.; Annicotte, J.S.; Fajas, L.; Foretz, M.; Verdeguer, F.; et al. PPARγ contributes to PKM2 and HK2 expression in fatty liver. *Nat. Commun.* **2012**, *3*, [CrossRef]

298. Wang, Y.; Nakajima, T.; Gonzalez, F.J.; Tanaka, N. PPARs as metabolic regulators in the liver: Lessons from liver-specific PPAR-null mice. *Int. J. Mol. Sci.* **2020**, *21*, 2061. [CrossRef]

299. Wahli, W.; Michalik, L. PPARs at the crossroads of lipid signaling and inflammation. *Trends Endocrinol. Metab.* **2012**, *23*, 351–363. [CrossRef]

300. Stienstra, R.; Mandard, S.; Tan, N.S.; Wahli, W.; Trautwein, C.; Richardson, T.A.; Lichtenauer-Kaligis, E.; Kersten, S.; Müller, M. The Interleukin-1 receptor antagonist is a direct target gene of PPARα in liver. *J. Hepatol.* **2007**, *46*, 869–877. [CrossRef]

301. Pawlak, M.; Baugé, E.; Bourguet, W.; De Bosscher, K.; Lalloyer, F.; Tailleux, A.; Lebherz, C.; Lefebvre, P.; Staels, B. The transrepressive activity of peroxisome proliferator-activated receptor alpha is necessary and sufficient to prevent liver fibrosis in mice. *Hepatology* **2014**, *60*, 1593–1606. [CrossRef]

302. Devchand, P.R.; Keller, H.; Peters, J.M.; Vazquez, M.; Gonzalez, F.J.; Wahli, W. The PPARα-leukotriene B4 pathway to inflammation control. *Nature* **1996**, *384*, 39–43. [CrossRef]
303. Jordan, S.; Tung, N.; Casanova-Acebes, M.; Chang, C.; Cantoni, C.; Zhang, D.; Wirtz, T.H.; Naik, S.; Rose, S.A.; Brocker, C.N.; et al. Dietary Intake Regulates the Circulating Inflammatory Monocyte Pool. *Cell* **2019**, *178*, 1102–1114.e17. [CrossRef] [PubMed]

304. Brocker, C.N.; Yue, J.; Kim, D.; Qu, A.; Bonzo, J.A.; Gonzalez, F.J. Hepatocyte-specific PPARA expression exclusively promotes agonist-induced cell proliferation without influence from nonparenchymal cells. *Am. J. Physiol. Gastrointest. Liver Physiol.* **2017**, *312*, G283–G299. [CrossRef] [PubMed]

305. Ip, E.; Farrell, G.; Hall, P.; Robertson, G.; Leclercq, I. Administration of the Potent PPARα Agonist, Wy-14,643, Reverses Nutritional Fibrosis and Steatohepatitis in Mice. *Hepatology* **2004**, *39*, 1286–1296. [CrossRef] [PubMed]

306. Chen, L.; Li, L.; Chen, J.; Li, L.; Zheng, Z.; Ren, J.; Qiu, Y. Oleylethanolamide, an endogenous PPAR-α ligand, attenuates liver fibrosis targeting hepatic stellate cells. *Oncotarget* **2015**, *6*, 42530–42540. [CrossRef]

307. Odegaard, J.I.; Ricardo-Gonzalez, R.R.; Red Eagle, A.; Vats, D.; Morel, C.R.; Goforth, M.H.; Subramanian, V.; Mukundan, L.; Ferrante, A.W.; Chawla, A. Alternative M2 Activation of Kupffer Cells by PPARδ Ameliorates Obesity-Induced Insulin Resistance. *Cell Metab.* **2008**, *7*, 496–507. [CrossRef]

308. Chen, J.; Zhuang, Y.; Sng, M.K.; Tan, N.S.; Wahli, W. The potential of the FSP1cre-Pparb/d−/− mouse model for studying Juvenile NAFLD. *Int. J. Mol. Sci.* **2019**, *20*, 5115. [CrossRef]

309. Kostadinova, R.; Montagner, A.; Gouranton, E.; Fleury, S.; Guillou, H.; Dombrowicz, D.; Desreumaux, P.; Wahli, W. GW501516-activated PPARβ/δ promotes liver fibrosis via p38-JNK MAPK-induced hepatic stellate cell proliferation. *Cell Biosci.* **2012**, *2*. [CrossRef]

310. Hellemans, K.; Michalik, L.; Dittie, A.; Knorr, A.; Rombouts, K.; De Jong, J.; Heirman, C.; Quartier, E.; Schuit, F.; Wahli, W.; et al. Peroxisome proliferator-activated receptor-β signaling contributes to enhanced proliferation of hepatic stellate cells. *Gastroenterology* **2003**, *124*, 184–201. [CrossRef]

311. Iwaisako, K.; Haimerl, M.; Paik, Y.H.; Taura, K.; Kodama, Y.; Sirlin, C.; Yu, E.; Yu, R.T.; Downes, M.; Evans, R.M.; et al. Protection from liver fibrosis by a peroxisome proliferator-activated receptor δ agonist. *Proc. Natl. Acad. Sci. USA* **2012**, *109*. [CrossRef]

312. Ricote, M.; Li, A.C.; Willson, T.M.; Kelly, C.J.; Glass, C.K. The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation. *Nature* **1998**, *391*, 79–82. [CrossRef]

313. Bouhlel, M.A.; Derudas, B.; Rigamonti, E.; Dièvart, R.; Brozek, J.; Haulon, S.; Zawadzki, C.; Jude, B.; Torpier, G.; Marx, N.; et al. PPARγ Activation Primes Human Monocytes into Alternative M2 Macrophages with Anti-inflammatory Properties. *Cell Metab.* **2007**, *6*, 137–143. [CrossRef]

314. Odegaard, J.I.; Ricardo-Gonzalez, R.R.; Goforth, M.H.; Morel, C.R.; Subramanian, V.; Mukundan, L.; Eagle, A.R.; Vats, D.; Brombacher, F.; Ferrante, A.W.; et al. Macrophage-specific PPARγ controls alternative activation and improves insulin resistance. *Nature* **2007**, *447*, 1116–1120. [CrossRef] [PubMed]

315. Luo, W.; Xu, Q.; Wang, Q.; Wu, H.; Hua, J. Effect of modulation of PPAR-γ activity on Kupffer cells M1/M2 polarization in the development of non-alcoholic fatty liver disease. *Sci. Rep.* **2017**, *7*. [CrossRef]

316. Cipolletta, D.; Feuerer, M.; Li, A.; Kamei, N.; Lee, J.; Shoelson, S.E.; Benoist, C.; Mathis, D. PPAR-γ is a major driver of the accumulation and phenotype of adipose tissue T reg cells. *Nature* **2012**, *486*, 549–553. [CrossRef]

317. Miyahara, T.; Schrum, L.; Rippe, R.; Xiong, S.; Yee, J.; Motomura, K.; Anania, F.A.; Willson, T.M.; Tsukamoto, H. Peroxisome proliferator-activated receptors and hepatic stellate cell activation. *J. Biol. Chem.* **2000**, *275*, 35715–35722. [CrossRef] [PubMed]

318. Hazra, S.; Xiong, S.; Wang, J.; Rippe, R.A.; Chatterjee, V.K.K.; Tsukamoto, H. Peroxisome Proliferator-activated Receptor γ Induces a Phenotypic Switch from Activated to Quiescent Hepatic Stellate Cells. *J. Biol. Chem.* **2004**, *279*, 11392–11401. [CrossRef] [PubMed]

319. Galli, A.; Crabb, D.W.; Ceni, E.; Salzano, R.; Mello, T.; Svegliati-Baroni, G.; Ridolfi, F.; Trozzi, L.; Currenti, C.; Casini, A. Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro. *Gastroenterology* **2002**, *122*, 1924–1940. [CrossRef] [PubMed]

320. Morán-Salvador, E.; Titos, E.; Rius, B.; González-Périz, A.; García-Alonso, V.; López-Vicario, C.; Miquel, R.; Barak, Y.; Arroyo, V.; Clària, J. Cell-specific PPARγ deficiency establishes anti-inflammatory and anti-fibrogenic properties for this nuclear receptor in non-parenchymal liver cells. *J. Hepatol.* **2013**, *59*, 1045–1053. [CrossRef]

321. Mandard, S.; Müller, M.; Kersten, S. Peroxisome proliferator-activated receptor α target genes. *Cell. Mol. Life Sci.* **2004**, *61*, 393–416. [CrossRef]
322. Kersten, S.; Rakhshandehroo, M.; Knoch, B.; Müller, M. Peroxisome proliferator-activated receptor alpha target genes. *PPAR Res.* **2010**, *2010*. [CrossRef]

323. Francque, S.; Verrijken, A.; Caron, S.; Prawitt, J.; Paumelle, R.; Derudas, B.; Lefebvre, P.; Taskinen, M.R.; Van Hul, W.; Mertens, I.; et al. PPARα gene expression correlates with severity and histological treatment response in patients with non-alcoholic steatohepatitis. *J. Hepatol.* **2015**, *63*, 164–173. [CrossRef]

324. Costet, P.; Legendre, C.; Moré, J.; Edgar, A.; Galtier, P.; Pineau, T. Peroxisome proliferator-activated receptor alpha-isoform deficiency leads to progressive dyslipidemia with sexually dimorphic obesity and steatosis. *J. Biol. Chem.* **1998**, *273*, 29577–29585. [CrossRef] [PubMed]

325. Stienstra, R.; Mandard, S.; Patsouris, D.; Maass, C.; Kersten, S.; Müller, M. Peroxisome proliferator-activated receptor α protects against obesity-induced hepatic inflammation. *Endocrinology* **2007**, *148*, 2753–2763. [CrossRef]

326. Abdelmegeed, M.A.; Yoo, S.-H.; Henderson, L.E.; Gonzalez, F.J.; Woodcroft, K.J.; Song, B.-J. PPARα Expression Protects Male Mice from High Fat-Induced Nonalcoholic Fatty Liver. *J. Nutr.* **2011**, *141*, 603–610. [CrossRef] [PubMed]

327. Ip, E.; Farrell, G.C.; Robertson, G.; Hall, P.; Kirsch, R.; Leclercq, I. Central role of PPARα-dependent hepatic lipid turnover in dietary steatohepatitis in mice. *Hepatology* **2003**, *38*, 123–132. [CrossRef] [PubMed]

328. Hu, X.; Tanaka, N.; Guo, R.; Lu, Y.; Nakajima, T.; Gonzalez, F.J.; Aoyama, T. PPARα protects against trans-fatty-acid-containing diet-induced steatohepatitis. *J. Nutr. Biochem.* **2017**, *39*, 77–85. [CrossRef] [PubMed]

329. Régnier, M.; Polizzi, A.; Smati, S.; Lukowicz, C.; Fougerat, A.; Lippi, Y.; Fouché, E.; Lasserre, F.; Naylies, C.; Bétoulières, C.; et al. Hepatocyte-specific deletion of Pparα promotes NAFLD in the context of obesity. *Sci. Rep.* **2020**, *10*. [CrossRef]

330. Liang, N.; Damdimopoulos, A.; Goñi, S.; Huang, Z.; Vedin, L.L.; Jakobsson, T.; Giudici, M.; Ahmed, O.; Pedrelli, M.; Barilla, S.; et al. Hepatocyte-specific loss of GPS2 in mice reduces non-alcoholic steatohepatitis via activation of PPARα. *Nat. Commun.* **2019**, *10*. [CrossRef]

331. Shan, W.; Nicol, C.J.; Ito, S.; Bility, M.T.; Kennett, M.J.; Ward, J.M.; Gonzalez, F.J.; Peters, J.M. Peroxisome proliferator-activated receptor-β/δ protects against chemically induced liver toxicity in mice. *Hepatology* **2008**, *47*, 225–235. [CrossRef] [PubMed]

332. Barak, Y.; Nelson, M.C.; Ong, E.S.; Jones, Y.Z.; Ruiz-Lozano, P.; Chien, K.R.; Koder, A.; Evans, R.M. PPARγ is required for placental, cardiac, and adipose tissue development. *Mol. Cell* **1999**, *4*, 585–595. [CrossRef]

333. Nadra, K.; Anghel, S.I.; Joye, E.; Tan, N.S.; Basu-Modak, S.; Trono, D.; Wahli, W.; Desvergne, B. Differentiation of Trophoblast Giant Cells and Their Metabolic Functions Are Dependent on Peroxisome Proliferator-Activated Receptor β/δ. *Mol. Cell. Biol.* **2006**, *26*, 3266–3281. [CrossRef] [PubMed]

334. Gilardi, F.; Winkler, C.; Quignodon, L.; Diserens, J.G.; Toffoli, B.; Schiffrin, M.; Sardella, C.; Preitner, F.; Desvergne, B. Systemic PPARγ deletion in mice provokes lipoatrophy, organomegaly, severe type 2 diabetes and metabolic inflexibility. *Metabolism* **2019**, *95*, 8–20. [CrossRef] [PubMed]

335. Morán-Salvador, E.; López-Parra, M.; García-Alonso, V.; Titos, E.; Martínez-Clemente, M.; González-Périz, A.; López-Vicario, C.; Barak, Y.; Arroyo, V.; Clària, J. Role for PPARγ in obesity-induced hepatic steatosis as determined by hepatocyte- and macrophage-specific conditional knockouts. *FASEB J.* **2011**, *25*, 2538–2550. [CrossRef] [PubMed]

336. Greenstein, A.W.; Majumdar, N.; Yang, P.; Subbaiah, P.V.; Kineman, R.D.; Cordoba-Chacon, J. Hepatocyte-specific, PPARγ-regulated mechanisms to promote steatosis in adult mice. *J. Endocrinol.* **2017**, *232*, 107–121. [CrossRef] [PubMed]

337. Patitucci, C.; Couchy, G.; Bagattin, A.; Cañeque, T.; De Reyniès, A.; Scoazec, J.Y.; Rodriguez, R.; Pontoglio, M.; Zucman-Rossi, J.; Pende, M.; et al. Hepatocyte nuclear factor 1α suppresses steatosis-associated liver cancer by inhibiting PPARγ transcription. *J. Clin. Invest.* **2017**, *127*, 1873–1888. [CrossRef] [PubMed]

338. Duszka, K.; Ellero-Simatos, S.; Ow, G.S.; Defernez, M.; Paramalingam, E.; Tett, A.; Ying, S.; König, J.; Narbad, A.; Kuznetsov, V.A.; et al. Complementary intestinal mucosa and microbiota responses to caloric restriction. *Sci. Rep.* **2018**, *8*. [CrossRef] [PubMed]

339. Montagner, A.; Korecka, A.; Polizzi, A.; Lippi, Y.; Blum, Y.; Canlet, C.; Tremblay-Franco, M.; Gautier-Stein, A.; Burcelin, R.; Yen, Y.-C.C.; et al. Hepatic circadian clock oscillators and nuclear receptors integrate microbiome-derived signals. *Sci. Rep.* **2016**, *6*, 20127. [CrossRef] [PubMed]
340. Ul Hasan, A.; Rahman, A.; Kobori, H. Interactions between host PPARs and gut microbiota in health and disease. *Int. J. Mol. Sci.* **2019**, *20*, 387. [CrossRef]

341. Choudhary, N.S.; Kumar, N.; Duseja, A. Peroxisome Proliferator-Activated Receptors and Their Agonists in Nonalcoholic Fatty Liver Disease. *J. Clin. Exp. Hepatol.* **2019**, *9*, 731–739. [CrossRef]

342. Boeckmans, J.; Natale, A.; Rombaut, M.; Buyl, K.; Rogiers, V.; De Kock, J.; Vanhaecke, T.; Rodrigues, R.M. Anti-NASH Drug Development Hitches a Lift on PPAR Agonism. *Cells* **2019**, *9*, 37. [CrossRef]

343. Okopień, B.; Bułdak, Ł.; Boldys, A. Benefits and risks of the treatment with fibrates—a comprehensive summary. *Expert Rev. Clin. Pharmacol.* **2018**, *11*, 1099–1112. [CrossRef]

344. Larter, C.Z.; Yeh, M.M.; van Rooyen, D.M.; Brooling, J.; Ghatora, K.; Farrell, G.C. Peroxisome proliferator-activated receptor-α agonist, Wy 14643, improves metabolic indices, steatosis and ballooning in diabetic mice with non-alcoholic steatohepatitis. *J. Gastroenterol. Hepatol.* **2012**, *27*, 341–350. [CrossRef]

345. Toyama, T.; Nakamura, H.; Harano, Y.; Yamauchi, N.; Morita, A.; Kirishima, T.; Minami, M.; Itoh, Y.; Okanoue, T. PPARα ligands activate antioxidant enzymes and suppress hepatic fibrosis in rats. *Biochem. Biophys. Res. Commun.* **2004**, *324*, 697–704. [CrossRef] [PubMed]

346. Rodríguez-Vilarrupla, A.; Laviña, B.; García-Calderó, H.; Russo, L.; Rosado, E.; Roglans, N.; Bosch, J.; García-Pagán, J.C. PPARα activation improves endothelial dysfunction and reduces fibrosis and portal pressure in cirrhotic rats. *J. Hepatol.* **2012**, *56*, 1033–1039. [CrossRef] [PubMed]

347. Nikam, A.; Patankar, J.V.; Somlapura, M.; Lahiri, P.; Sachdev, V.; Kratky, D.; Denk, H.; Zatloukal, K.; Abuja, P.M. The PPARα Agonist Fenofibrate Prevents Formation of Protein Aggregates (Mallory-Denk bodies) in a Murine Model of Steatohepatitis-like Hepatotoxicity. *Sci. Rep.* **2018**, *8*. [CrossRef] [PubMed]

348. Fabbrini, E.; Mohammed, B.S.; Korenblat, K.M.; Magkos, F.; McCrea, J.; Patterson, B.W.; Klein, S. Effect of Fenofibrate and Niacin on Intrahepatic Triglyceride Content, Very Low-Density Lipoprotein Kinetics, and Insulin Action in Obese Subjects with Nonalcoholic Fatty Liver Disease. *J. Clin. Endocrinol. Metab.* **2010**, *95*, 2727. [CrossRef]

349. Fernández-Miranda, C.; Pérez-Carreras, M.; Colina, F.; López-Alonso, G.; Vargas, C.; Solís-Herruzo, J.A. A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease. *Dig. Liver Dis.* **2008**, *40*, 200–205. [CrossRef]

350. El-Haggar, S.M.; Mostafa, T.M. Comparative clinical study between the effect of fenofibrate alone and its combination with pentoxifylline on biochemical parameters and liver stiffness in patients with non-alcoholic fatty liver disease. *Hepatol. Int.* **2015**, *9*, 471–479. [CrossRef] [PubMed]

351. Oscarsson, J.; Önnerhag, K.; Risérus, U.; Sundén, M.; Johansson, L.; Jansson, P.A.; Moris, L.; Nilsson, P.M.; Eriksson, J.W.; Lind, L. Effects of free omega-3 carboxylic acids and fenofibrate on liver fat content in patients with hypertriglyceridemia and non-alcoholic fatty liver disease: A double-blind, randomized, placebo-controlled study. *J. Clin. Lipidol.* **2018**, *12*, 1390–1403.e4. [CrossRef]

352. Roy, A.; Pahan, K. Gemfibrozil, stretching arms beyond lipid lowering. *Immunopharmacol. Immunotoxicol.* **2009**, *31*, 339–351. [CrossRef]

353. Zhang, X.; Wang, S.; Hu, L.; Wang, J.; Liu, Y.; Shi, P. Gemfibrozil reduces lipid accumulation in smmc-7721 cells via the involvement of pparα and srebp1. *Exp. Ther. Med.* **2019**, *17*, 1282–1289. [CrossRef]

354. Basaranoglu, M.; Acbay, O.; Sonsuz, A. A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis. *J. Hepatol.* **1999**, *31*, 384. [CrossRef]

355. Yaghoubi, M.; Jafari, S.; Sajedi, B.; Gohari, S.; Akbarieh, S.; Heydari, A.H.; Jameshoorani, M. Comparison of fenofibrate and pioglitazone effects on patients with nonalcoholic fatty liver disease. *Eur. J. Gastroenterol. Hepatol.* **2017**, *29*, 1385–1388. [CrossRef]

356. Garbacz, W.G.; Huang, J.T.J.; Higgins, L.G.; Wahli, W.; Palmer, C.N.A. PPAR Is Required for PPAR δ Action in Regulation of Body Weight and Hepatic Steatosis in Mice. *PPAR Res.* **2015**, *2015*. [CrossRef] [PubMed]

357. Tanaka, T.; Yamamoto, J.; Iwasaki, S.; Asaba, H.; Hamura, H.; Ikeda, Y.; Watanabe, M.; Magoori, K.; Ioka, R.X.; Tachibana, K.; et al. Activation of peroxisome proliferator-activated receptor δ induces fatty acid β-oxidation in skeletal muscle and attenuates metabolic syndrome. *Proc. Natl. Acad. Sci. USA* **2003**, *100*, 15924–15929. [CrossRef]

358. Zarei, M.; Barroso, E.; Palomer, X.; Escolà-Gil, J.C.; Cedó, L.; Wahli, W.; Vázquez-Carrera, M. Pharmacological PPARβ/δ activation upregulates VLDLR in hepatocytes. *Clin. e Investig. en Arterioscler.* **2019**, *31*, 111–118. [CrossRef] [PubMed]

359. Bojic, L.A.; Telford, D.E.; Fullerton, M.D.; Ford, R.J.; Sutherland, B.G.; Edwards, J.Y.; Sawyez, C.G.; Gros, R.; Kemp, B.E.; Steinberg, G.R.; et al. PPAR—Activation attenuates hepatic steatosis in Ldlr Mice by enhanced fat oxidation, reduced lipogenesis, and improved insulin sensitivity. *J. Lipid Res.* **2014**, *55*, 1254–1266. [CrossRef]
360. Chung, C.H.; Lee, M.Y.; Choi, R.; Kim, H.M.; Cho, E.J.; Kim, B.H.; Choi, Y.S.; Naowaboot, J.; Lee, E.Y.; Yang, Y.C.; et al. Peroxisome proliferator-activated receptor δ agonist attenuates hepatic steatosis by anti-inflammatory mechanism. *Exp. Mol. Med.* **2012**, *44*, 578–585. [CrossRef]

361. Silva-Veiga, F.M.; Rachid, T.L.; de Oliveira, L.; Graus-Nunes, F.; Mandarim-de-Lacerda, C.A.; Souza-Mello, V. GW0742 (PPAR-beta agonist) attenuates hepatic endoplasmic reticulum stress by improving hepatic energy metabolism in high-fat diet fed mice. *Mol. Cell. Endocrinol.* **2018**, *474*, 227–237. [CrossRef]

362. Shan, W.; Palkar, P.S.; Murray, I.A.; Mcdevitt, E.I.; Kennett, M.J.; Kang, B.H.; Isom, H.C.; Perdew, G.H.; Gonzalez, F.J.; Peters, J.M. Ligand activation of peroxisome proliferator—Activated receptor β/δ (PPARβ/δ) attenuates carbon tetrachloride hepatotoxicity by downregulating proinflammatory gene expression. *Toxicol. Sci.* **2008**, *105*, 418–428. [CrossRef]

363. Haczeyni, F.; Wang, H.; Barn, V.; Mridha, A.R.; Yeh, M.M.; Haigh, W.G.; Ioannou, G.N.; Choi, Y.-J.; McWherter, C.A.; Teoh, N.C.-H.; et al. The selective peroxisome proliferator-activated receptor-delta agonist seladelpar reverses nonalcoholic steatohepatitis pathology by abrogating lipotoxicity in diabetic obese mice. *Hepatol. Commun.* **2017**, *1*, 663–674. [CrossRef] [PubMed]

364. Daniels, S.J.; Leeming, D.J.; Detlefsen, S.; Bruun, M.F.; Hjuler, S.T.; Henriksen, K.; Hein, P.; Karsdal, M.A.; Brockbank, S.; Cruwys, S. Biochemical and histological characterisation of an experimental rodent model of non-alcoholic steatohepatitis – Effects of a peroxisome proliferator-activated receptor gamma (PPAR-γ) agonist and a glucagon-like peptide-1 analogue. *Biomed. Pharmacother.* **2019**, *111*, 926–933. [CrossRef]

365. Ahn, H.Y.; Kim, H.H.; Hwang, J.Y.; Park, C.; Cho, B.Y.; Park, Y.J. Effects of pioglitazone on nonalcoholic fatty liver disease in the absence of constitutive androstane receptor expression. *PPAR Res.* **2018**, *2018*. [CrossRef] [PubMed]

366. Jia, C.; Huan, Y.; Liu, S.; Hou, S.; Sun, S.; Li, C.; Liu, Q.; Jiang, Q.; Wang, Y.; Shen, Z. Effect of chronic pioglitazone treatment on hepatic gene expression profile in obese C57BL/6J mice. *Int. J. Mol. Sci.* **2015**, *16*, 12213–12229. [CrossRef]

367. Musso, G.; Cassader, M.; Paschetta, E.; Gambino, R. Thiazolidinediones and advanced liver fibrosis in nonalcoholic steatohepatitis: A meta-analysis. *JAMA Intern. Med.* **2017**, *177*, 633–640. [CrossRef]

368. Wu, H.M.; Ni, X.X.; Xu, Q.Y.; Wang, Q.; Li, X.Y.; Hua, J. Regulation of lipid-induced macrophage polarization through modulating peroxisome proliferator-activated receptor-gamma activity affects hepatic lipid metabolism via a Toll-like receptor 4/NF-κB signaling pathway. *J. Gastroenterol. Hepatol.* **2020**. [CrossRef]

369. Nan, Y.M.; Fu, N.; Wu, W.J.; Liang, B.L.; Wang, R.Q.; Zhao, S.X.; Zhao, J.M.; Yu, J. Rosiglitazone prevents nutritional fibrosis and steatohepatitis in mice. *Scand. J. Gastroenterol.* **2009**, *44*, 358–365. [CrossRef]

370. Wei, Z.; Zhao, D.; Zhang, Y.; Chen, Y.; Zhang, S.; Li, Q.; Zeng, P.; Li, X.; Zhang, W.; Duan, Y.; et al. Rosiglitazone ameliorates bile duct ligation-induced liver fibrosis by down-regulating NF-κB-TNF-α signaling pathway in a PPARγ-dependent manner. *Biochem. Biophys. Res. Commun.* **2019**, *519*, 854–860. [CrossRef] [PubMed]

371. Wang, Q.A.; Zhang, F.; Jiang, L.; Ye, R.; An, Y.; Shao, M.; Tao, C.; Gupta, R.K.; Scherer, P.E. Peroxisome Proliferator-Activated Receptor γ and Its Role in Adipocyte Homeostasis and Thiazolidinedione-Mediated Insulin Sensitization. *Mol. Cell. Biol.* **2018**, *38*. [CrossRef] [PubMed]

372. Neuschwander-Tetri, B.A.; Brunt, E.M.; Wehmeier, K.R.; Oliver, D.; Bacon, B.R. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-γ ligand rosiglitazone. *Hepatology* **2003**, *38*, 1008–1017. [CrossRef] [PubMed]

373. Ratziu, V.; Giral, P.; Jacqueminet, S.; Charlotte, F.; Hartemann-Heurtier, A.; Serfaty, L.; Podevin, P.; Lacorte, J.M.; Bernhardt, C.; Bruckert, E.; et al. Rosiglitazone for Nonalcoholic Steatohepatitis: One-Year Results of the Randomized Placebo-Controlled Fatty Liver Improvement With Rosiglitazone Therapy (FLIRT) Trial. *Gastroenterology* **2008**, *135*, 100–110. [CrossRef] [PubMed]

374. Lemoine, M.; Serfaty, L.; Cervera, P.; Capeau, J.; Ratziu, V. Hepatic molecular effects of rosiglitazone in human non-alcoholic steatohepatitis suggest long-term pro-inflammatory damage. *Hepatol. Res.* **2014**, *44*, 1241–1247. [CrossRef] [PubMed]

375. Fruchart, J.C.; Santos, R.D.; Aguilar-Salinas, C.; Aikawa, M.; Al Rasadi, K.; Amarenco, P.; Barter, P.J.; Ceska, R.; Corsini, A.; Després, J.P.; et al. The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: Conceptual framework and therapeutic potential. *Cardiovasc. Diabetol.* **2019**, *18*, 71. [CrossRef] [PubMed]
376. Kawasaki, M.; Kambe, A.; Yamamoto, Y.; Arulmozhiraja, S.; Ito, S.; Nakagawa, Y.; Tokiwa, H.; Nakano, S.; Shimano, H. Elucidation of molecular mechanism of a selective PPARα modulator, pemafibrate, through combinational approaches of x-ray crystallography, thermodynamic analysis, and first-principle calculations. *Int. J. Mol. Sci.* **2020**, *21*, 361. [CrossRef]

377. Raza-Iqbal, S.; Tanaka, T.; Anai, M.; Inagaki, T.; Matsumura, Y.; Ikeda, K.; Taguchi, A.; Gonzalez, F.J.; Sakai, J.; Kodama, T. Transcriptome analysis of K-877 (A novel selective PPARα modulator (SPPARMα))-regulated genes in primary human hepatocytes and the mouse liver. *J. Atheroscler. Thromb.* **2015**, *22*, 754–772. [CrossRef]

378. Sasaki, Y.; Raza-Iqbal, S.; Tanaka, T.; Murakami, K.; Anai, M.; Osawa, T.; Matsumura, Y.; Sakai, J.; Kodama, T. Gene expression profiles induced by a novel selective peroxisome proliferator-activated receptor α modulator (SPPARMA) pemafibrate. *Int. J. Mol. Sci.* **2019**, *20*, 5682. [CrossRef]

379. Takei, K.; Nakagawa, Y.; Wang, Y.; Han, S.-I.; Satoh, A.; Sekiya, M.; Matsuzaka, T.; Shimano, H. Effects of K-877, a novel selective PPARα modulator, on small intestine contribute to the amelioration of hyperlipidemia in low-density lipoprotein receptor knockout mice. *J. Pharmacol. Sci.* **2017**, *133*, 214–222. [CrossRef]

380. Hennuyer, N.; Duplan, I.; Paquet, C.; Vanhoutte, J.; Woitrain, E.; Touche, V.; Colin, S.; Vallez, E.; Lestavel, S.; Lefebvre, P.; et al. The novel selective PPARα modulator (SPPARMα) pemafibrate improves dyslipidemia, enhances reverse cholesterol transport and decreases inflammation and atherosclerosis. *Atherosclerosis* **2016**, *249*, 200–208. [CrossRef]

381. Sairyo, M.; Kobayashi, T.; Masuda, D.; Kanno, K.; Zhu, Y.; Okada, T.; Koseki, M.; Ohama, T.; Nishida, M.; Sakata, Y.; et al. A novel selective PPARα modulator (SPPARMα), K-877 (pemafibrate), attenuates postprandial hypertriglyceridemia in mice. *J. Atheroscler. Thromb.* **2018**, *25*, 142–152. [CrossRef]

382. Araki, M.; Nakagawa, Y.; Oishi, A.; Han, S.I.; Wang, Y.; Kumagai, K.; Ohno, H.; Mizunoe, Y.; Iwasaki, H.; Sekiya, M.; et al. The peroxisome proliferator-activated receptor α (PPARα) agonist pemafibrate protects against diet-induced obesity in mice. *Int. J. Mol. Sci.* **2018**, *19*, 2148. [CrossRef]

383. Honda, Y.; Kessoku, T.; Ogawa, Y.; Tomeno, W.; Imajo, K.; Fujita, K.; Yoneda, M.; Takizawa, T.; Saito, S.; Nagashima, Y.; et al. Pemafibrate, a novel selective peroxisome proliferator-activated receptor alpha modulator, improves the pathogenesis in a rodent model of nonalcoholic steatohepatitis. *Sci. Rep.* **2017**, *7*, 42477. [CrossRef] [PubMed]

384. Sasaki, Y.; Asahiyama, M.; Tanaka, T.; Yamamoto, S.; Murakami, K.; Kamiya, W.; Matsumura, Y.; Osawa, T.; Anai, M.; Fruchart, J.C.; et al. Pemafibrate, a selective PPARα modulator, prevents non-alcoholic steatohepatitis development without reducing the hepatic triglyceride content. *Sci. Rep.* **2020**, *10*. [CrossRef]

385. Yamashita, S.; Arai, H.; Yokote, K.; Araki, E.; Matsushita, M.; Nojima, T.; Suganami, H.; Ishibashi, S. Efficacy and safety of pemafibrate, a novel selective peroxisome proliferator-activated receptor α modulator (SPPARMα): Pooled analysis of phase 2 and 3 studies in dyslipidemic patients with or without statin combination. *Int. J. Mol. Sci.* **2019**, *20*, 5537. [CrossRef] [PubMed]

386. Ishibashi, S.; Arai, H.; Yokote, K.; Araki, E.; Suganami, H.; Yamashita, S. Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor α modulator, in patients with dyslipidemia: Results from a 24-week, randomized, double blind, active-controlled, phase 3 trial. *J. Clin. Lipidol.* **2018**, *12*, 173–184. [CrossRef] [PubMed]

387. Arai, H.; Yamashita, S.; Yokote, K.; Araki, E.; Suganami, H.; Ishibashi, S. Efficacy and safety of pemafibrate versus fenofibrate in patients with high triglyceride and low HDL cholesterol levels: A multicenter, placebo-controlled, double-blind, randomized trial. *J. Atheroscler. Thromb.* **2018**, *25*, 521–538. [CrossRef]

388. Ida, S.; Kaneko, R.; Murata, K. Efficacy and safety of pemafibrate administration in patients with dyslipidemia: A systematic review and meta-analysis. *Cardiovasc. Diabetol.* **2019**, *18*. [CrossRef]

389. Araki, E.; Yamashita, S.; Arai, H.; Yokote, K.; Satoh, J.; Inoguchi, T.; Nakamura, J.; Maegawa, H.; Yoshioka, N.; Tanizawa, Y.; et al. Effects of pemafibrate, a novel selective PPARα modulator, on lipid and glucose metabolism in patients with type 2 diabetes and hypertriglyceridemia: A randomized, double-blind, placebo-controlled, phase 3 trial. *Diabetes Care* **2018**, *41*, 538–546. [CrossRef]

390. Pradhan, A.D.; Paynter, N.P.; Everett, B.M.; Glynn, R.J.; Amarenco, P.; Elam, M.; Ginsberg, H.; Hiatt, W.R.; Ishibashi, S.; Koenig, W.; et al. Rationale and design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study. *Am. Heart J.* **2018**, *206*, 80–93. [CrossRef] [PubMed]

391. Westerouen Van Meeteren, M.J.; Drenth, J.P.H.; Tjwa, E.T.T.L. Elafibranor: A potential drug for the treatment of nonalcoholic steatohepatitis (NASH). *Expert Opin. Investig. Drugs* **2020**, *29*, 117–123. [CrossRef] [PubMed]
392. Staels, B.; Rubenstrunk, A.; Noel, B.; Rigou, G.; Delataille, P.; Millatt, L.J.; Baron, M.; Lucas, A.; Tailleux, A.; Hum, D.W.; et al. Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. *Hepatology* **2013**, *58*. [CrossRef] [PubMed]

393. Tølbøl, K.S.; Kristiansen, M.N.; Hansen, H.H.; Veidal, S.S.; Rigbolt, K.T.; Gillum, M.P.; Jelsing, J.; Vrang, N.; Feigh, M. Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis. *World J. Gastroenterol.* **2018**, *24*, 179–194. [CrossRef]

394. Roth, J.D.; Veidal, S.S.; Fensholdt, L.K.D.; Rigbolt, K.T.G.; Papazyan, R.; Nielsen, J.C.; Feigh, M.; Vrang, N.; Young, M.; Jelsing, J.; et al. Combined obeticholic acid and elafibranor treatment promotes additive liver histological improvements in a diet-induced ob/ob mouse model of biopsy-confirmed NASH. *Sci. Rep.* **2019**, *9*. [CrossRef] [PubMed]

395. Briand, F.; Heymes, C.; Bonada, L.; Angles, T.; Charpentier, J.; Branchereau, M.; Brousseau, E.; Quinsat, M.; Fazilleau, N.; Burcelin, R.; et al. A 3-week nonalcoholic steatohepatitis mouse model shows elafibranor benefits on hepatic inflammation and cell death. *Clin. Transl. Sci.* **2020**, *13*. [CrossRef] [PubMed]

396. Li, T.H.; Yang, Y.Y.; Huang, C.C.; Liu, C.W.; Tsai, H.C.; Lin, M.W.; Tsai, C.Y.; Huang, S.F.; Wang, Y.W.; Lee, T.Y.; et al. Elafibranor interrupts adipose dysfunction-mediated gut and liver injury in mice with alcoholic steatohepatitis. *Clin. Sci.* **2019**, *133*, 531–544. [CrossRef]

397. Cariou, B.; Hanf, R.; Lambert-Porcheron, S.; Zair, Y.; Sauvinet, V.; Noel, B.; Flet, L.; Vidal, H.; Staels, B.; Laville, M. Dual peroxisome proliferator- activated receptor α/δ agonist gft505 improves hepatic and peripheral insulin sensitivity in abdominally obese subjects. *Diabetes Care* **2013**, *36*, 2923–2930. [CrossRef] [PubMed]

398. Ratziu, V.; Harrison, S.A.; Francque, S.; Bedossa, P.; Lehert, P.; Serfaty, L.; Romero-Gomez, M.; Boursier, J.; Abdelmalek, M.; Caldwell, S.; et al. Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis. *Worsening. Gastroenterology* **2016**, *150*, 1147–1159.e5. [CrossRef] [PubMed]

399. Agrawal, R. The First Approved Agent in the Glitazar's Class: Saroglitazar. *Curr. Drug Targets* **2014**, *15*, 151–155. [CrossRef] [PubMed]

400. Jain, M.R.; Giri, S.R.; Trivedi, C.; Bhoi, B.; Rath, A.; Vanage, G.; Vyas, P.; Ranvir, R.; Patel, P.R. Saroglitazar, a novel PPARα/γ agonist with predominant PPARα activity, shows lipid-lowering and insulin-sensitizing effects in preclinical models. *Pharmacol. Res. Perspect.* **2015**, *3*. [CrossRef] [PubMed]

401. Jain, M.R.; Giri, S.R.; Bhoi, B.; Trivedi, C.; Rath, A.; Rathod, R.; Ranvir, R.; Kadam, S.; Patel, H.; Swain, P.; et al. Dual PPARα/γ agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models. *Liver Int.* **2018**, *38*, 1084–1094. [CrossRef]

402. Kumar, D.; Goand, U.K.; Gupta, S.; Shankar, K.; Varshney, S.; Rajan, S.; Srivastava, A.; Gupta, A.; Vishwakarma, A.L.; Srivastava, A.K.; et al. Saroglitazar reduces obesity and associated inflammatory consequences in murine adipose tissue. *Eur. J. Pharmacol.* **2018**, *822*, 32–42. [CrossRef]

403. Hassan, N.F.; Nada, S.A.; Hassan, A.; El-Ansary, M.R.; Al-Shorbagy, M.Y.; Abdelsalam, R.M. Saroglitazar Deactivates the Hepatic LPS/TLR4 Signaling Pathway and Ameliorates Adipocyte Dysfunction in Rats with High-Fat Emulsion/LPS Model-Induced Non-alcoholic Steatohepatitis. *Inflammation* **2019**, *42*, 1056–1070. [CrossRef]

404. Makled, M.N.; Sharawy, M.H.; El-Awady, M.S. The dual PPAR-α/γ agonist saroglitazar ameliorates thioacetamide-induced liver fibrosis in rats through regulating leptin. *Naunyn. Schmiedebergs. Arch. Pharmacol.* **2019**, *392*, 1569–1576. [CrossRef] [PubMed]

405. Jani, R.H.; Pai, V.; Jha, P.; Jariwala, G.; Mukhopadhyay, S.; Bhansali, A.; Joshi, S. A multicenter, prospective, randomized, double-blind study to evaluate the safety and efficacy of saroglitazar 2 and 4 mg compared with placebo in type 2 diabetes mellitus patients having hypertriglyceridemia not controlled with atorvastatin therapy (PRESS VI). *Diabetes Technol. Ther.* **2014**, *16*, 63–71. [CrossRef]

406. Pai, V.; Paneerselvam, A.; Mukhopadhyay, S.; Bhansali, A.; Kamath, D.; Shankar, V.; Gambhire, D.; Jani, R.H.; Joshi, S.; Patel, P. A multicenter, prospective, randomized, double-blind study to evaluate the safety and efficacy of saroglitazar 2 and 4 mg compared to pioglitazone 45 mg in diabetic dyslipidemia (PRESS V). *J. Diabetes Sci. Technol.* **2014**, *8*, 132–141. [CrossRef] [PubMed]
407. Jain, N.; Bhansali, S.; Kurpad, A.V.; Hawkins, M.; Sharma, A.; Kaur, S.; Rastogi, A.; Bhansali, A. Effect of a Dual PPAR α/γ agonist on Insulin Sensitivity in Patients of Type 2 Diabetes with Hypertriglyceridemia-Randomized double-blind placebo-controlled trial. *Sci. Rep.* **2019**, *9*, [CrossRef]

408. Kaul, U.; Parmar, D.; Manjunath, K.; Shah, M.; Parmar, K.; Patil, K.P.; Jaiswal, A. New dual peroxisome proliferator activated receptor agonist—Saroglitazar in diabetic dyslipidemia and non-alcoholic fatty liver disease: Integrated analysis of the real world evidence. *Cardiovasc. Diabetol.* **2019**, *18*, 80. [CrossRef]

409. Boubia, B.; Poupardin, O.; Barth, M.; Binet, J.; Peralba, P.; Mounier, L.; Jacquier, E.; Gauthier, E.; Lepais, V.; Chatar, M.; et al. Design, Synthesis, and Evaluation of a Novel Series of Indole Sulfonamide Peroxisome Proliferator Activated Receptor (PPAR) α/γ/δ Triple Activators: Discovery of Lanifibranor, a New Antifibrotic Clinical Candidate. *J. Med. Chem.* **2018**, *61*, 2246–2265. [CrossRef]

410. Wettstein, G.; Luccarini, J.-M.; Poekes, L.; Faye, P.; Kupkowski, F.; Adarbes, V.; Defrêne, E.; Estivalet, C.; Gawronski, X.; Jantzen, I.; et al. The new-generation pan-peroxisome proliferator-activated receptor agonist IVA337 protects the liver from metabolic disorders and fibrosis. *Hepatol. Commun.* **2017**, *1*, 524–537. [CrossRef]

411. Lefere, S.; Puengel, T.; Hundertmark, J.; Penners, C.; Frank, A.K.; Guillot, A.; de Muynck, K.; Heymann, F.; Adarbes, V.; Defrêne, E.; et al. Differential effects of selective- and pan-PPAR agonists on experimental steatohepatitis and hepatic macrophages. *J. Hepatol.* **2020**. [CrossRef] [PubMed]

412. Ruzehaji, N.; Frantz, C.; Ponsoye, M.; Avouac, J.; Pezet, S.; Guilbert, T.; Luccarini, J.M.; Broqua, P.; Junien, J.L.; Allanore, Y. Pan PPAR agonist IVA337 is effective in prevention and treatment of experimental skin fibrosis. *Ann. Rheum. Dis.* **2016**, *75*, 2175–2183. [CrossRef]

413. Avouac, J.; Konstantinova, I.; Guignabert, C.; Pezet, S.; Sadoine, J.; Guilbert, T.; Cauvet, A.; Tu, L.; Luccarini, J.M.; Junien, J.L.; et al. Pan-PPAR agonist IVA337 is effective in experimental lung fibrosis and pulmonary hypertension. *Ann. Rheum. Dis.* **2017**, *76*, 1931–1940. [CrossRef]

414. Farrell, G.; Schattenberg, J.M.; Leclercq, I.; Yeh, M.M.; Goldin, R.; Teoh, N.; Schuppan, D. Mouse Models of Nonalcoholic Steatohepatitis: Toward Optimization of Their Relevance to Human Nonalcoholic Steatohepatitis. *Hepatology* **2019**, *69*, 2241–2257. [CrossRef] [PubMed]

415. Kang, Z.; Fan, R. PPARα and NCOR/SMRT corepressor network in liver metabolic regulation. *FASEB J.* **2020**. [CrossRef] [PubMed]

416. Kalliora, C.; Kyriazis, I.D.; Oka, S.I.; Lieu, M.J.; Yue, Y.; Area-Gomez, E.; Pol, C.J.; Tian, Y.; Mizushima, W.; Chin, A.; et al. Dual PPARα/γ activation inhibits SIRT1-PGC1α axis and causes cardiac dysfunction. *JCI Insight* **2019**, *4*, [CrossRef]

417. Li, S.; Yang, B.; Du, Y.; Lin, Y.; Liu, J.; Huang, S.; Zhang, A.; Jia, Z.; Zhang, Y. Targeting PPARα for the treatment and understanding of cardiovascular diseases. *Cell. Physiol. Biochem.* **2019**, *51*, 2760–2775. [CrossRef]

418. Krishnappa, M.; Patil, K.; Parmar, K.; Trivedi, P.; Mody, N.; Shah, C.; Faldu, K.; Maroo, S.; Parmar, D. Effect of saroglitazar 2 mg and 4 mg on glycemic control, lipid profile and cardiovascular disease risk in patients with type 2 diabetes mellitus: A 56-week, randomized, double blind, phase 3 study (PRESS XII study). *Cardiovasc. Diabetol.* **2020**, *19*, 93. [CrossRef] [PubMed]

419. Afroze, S.H.; Munshi, M.K.; Martínez, A.K.; Uddin, M.; Gergely, M.; Szynkarski, C.; Guerrier, M.; Nizamutdinov, D.; Dostal, D.; Glaser, S. Activation of the renin-angiotensin system stimulates biliary hyperplasia during cholestasis induced by extrahepatic bile duct ligation. *Am. J. Physiol. Gastrointest. Liver Physiol.* **2015**, *308*, G691–G701. [CrossRef] [PubMed]

420. Saran, A.R.; Dave, S.; Zarrinpar, A. Circadian Rhythms in the Pathogenesis and Treatment of Fatty Liver Disease. *Gastroenterology* **2020**, *158*. [CrossRef]

<figure><img src="image_9.png" /></figure>